Based on the hypothesis that excessive TNF-α accumulation may cause deleterious effects, a variety of treatments targeting TNF-α (such as Infliximab, Etanercept, Certolizumab pegol, Adalimumab) have been introduced in autoimmune diseases and have shown favorable performance (Chatzantoni and Mouzaki, 2006). The gene discussed is TNF; the disease is autoimmune disease.